APG Asset Management N.V. Purchases 22,349 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

APG Asset Management N.V. increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 288.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 30,104 shares of the medical research company's stock after buying an additional 22,349 shares during the period. APG Asset Management N.V. owned 0.06% of Charles River Laboratories International worth $5,367,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc lifted its stake in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after purchasing an additional 150 shares during the period. Pinnacle Bancorp Inc. lifted its stake in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares during the period. Pilgrim Partners Asia Pte Ltd bought a new position in shares of Charles River Laboratories International during the 4th quarter worth approximately $48,000. Tortoise Investment Management LLC grew its position in shares of Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after buying an additional 115 shares during the period. Finally, Huntington National Bank increased its stake in shares of Charles River Laboratories International by 120.6% in the 4th quarter. Huntington National Bank now owns 300 shares of the medical research company's stock valued at $55,000 after acquiring an additional 164 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of research firms have commented on CRL. Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Mizuho decreased their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. Barclays decreased their price objective on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. The Goldman Sachs Group cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Finally, Morgan Stanley lowered their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and an average target price of $182.00.

Insiders Place Their Bets

In related news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company's stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO James C. Foster acquired 6,075 shares of the business's stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL traded down $0.58 during mid-day trading on Tuesday, hitting $106.02. The company had a trading volume of 2,845,054 shares, compared to its average volume of 880,553. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a market capitalization of $5.21 billion, a price-to-earnings ratio of 706.79, a P/E/G ratio of 4.54 and a beta of 1.45. The stock's 50-day moving average price is $155.52 and its 200-day moving average price is $176.21.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's revenue was down 1.1% compared to the same quarter last year. During the same period last year, the business earned $2.46 earnings per share. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).